NCT05114746 2026-03-16
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT05670106 2026-02-13
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Novartis
Phase 2 Active not recruiting
NCT05160597 2026-02-12
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04777071 2026-01-09
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
Phase 2 Active not recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT04147494 2025-08-12
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03582774 2025-05-13
PSMA SRT
Jonsson Comprehensive Cancer Center
Phase 3 Active not recruiting
NCT03762759 2024-05-17
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Phase 2 Active not recruiting